MSD is spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company (“NewCo”)

“We have made the decision to separate into two growth companies: MSD and NewCo. By optimising our human health portfolio, MSD can move closer to its aspiration of being the premier research-intensive biopharmaceutical company, while also properly prioritising a set of products at NewCo that are important to public health and the patients who rely on them, and which present real opportunities for growth.”

Kenneth C. Frazier
MSD Chairman and CEO